Resources from the same session
3347 - CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors
Presenter: Emmanuel Antonarakis
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
2754 - Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): updated analyses
Presenter: Wassim Abida
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
5118 - Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study
Presenter: Johann de Bono
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
3623 - Phase II Study of Pembrolizumab with Enzalutamide (Enz) in Metastatic, Castration Resistant Prostate Cancer (mCRPC): 30 patient expansion with examination of tumor infiltrating immune cells and fecal microbiota
Presenter: Julie Graff
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
1823 - Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)
Presenter: Scott Tagawa
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
2495 - Docetaxel for hormone-naïve prostate cancer (PCa): results from long-term follow-up of non-metastatic (M0) patients in the STAMPEDE randomised trial (NCT00268476)
Presenter: Nicholas James
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
1199 - Benefit of prostate radiotherapy for patients with lymph node only or < 4 bone metastasis and no visceral metastases: Exploratory analyses of metastatic site and number in the STAMPEDE “M1_RT comparison”
Presenter: Syed Adnan Ali
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
1910 - Patient-Reported Outcomes (PROs) From TITAN: a Phase 3, Randomized, Double-Blind Study of Apalutamide (APA) Versus Placebo (PBO) Added to Androgen Deprivation Therapy (ADT) in Patients (pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Presenter: Neeraj Agarwal
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
3405 - Pre-specified interim analysis of GALAHAD: A phase 2 study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)
Presenter: Matthew Smith
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
Poster Discussion – Genitourinary tumours, prostate - Invited Discussant LBA50, 845PD, 846PD and 847PD
Presenter: Elena Castro
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Slides
Webcast